Warning: The NCBI web site requires JavaScript to function. more...
Simulation of the cost-effectiveness of malaria vaccines.
Tediosi F, Maire N, Penny M, Studer A, Smith TA.
Malar J. 2009 Jun 8;8:127.
Related citations
What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.
Penny MA, Maire N, Studer A, Schapira A, Smith TA.
PLoS One. 2008 Sep 11;3(9):e3193.
Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria.
Maire N, Shillcutt SD, Walker DG, Tediosi F, Smith TA.
Value Health. 2011 Dec;14(8):1028-38. Epub 2011 Aug 15.
Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania.
Tediosi F, Hutton G, Maire N, Smith TA, Ross A, Tanner M.
Am J Trop Med Hyg. 2006 Aug;75(2 Suppl):131-43.
Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine.
Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, Brooks A, Penny M, Tanner M.
PLoS Med. 2012 Jan;9(1):e1001157. Epub 2012 Jan 17.
Humoral immune responses during a malaria vaccine trial in Tanzanian infants.
Galindo CM, Acosta CJ, Schellenberg D, Aponte JJ, Roca A, Oettli A, Urassa H, Armstrong Schellenberg J, Kahigwa E, Ascaso C, Mshinda H, Lwilla F, Vidal J, Menendez C, Tanner M, Alonso PL.
Parasite Immunol. 2000 Sep;22(9):437-43.
Comparison of the cost-effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria.
Graves PM.
Ann Trop Med Parasitol. 1998 Jun;92(4):399-410.
Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview.
Smith T, Killeen GF, Maire N, Ross A, Molineaux L, Tediosi F, Hutton G, Utzinger J, Dietz K, Tanner M.
Am J Trop Med Hyg. 2006 Aug;75(2 Suppl):1-10.
The development of malaria vaccines: SPf66--what next?
Tanner M, Alonso PL.
Schweiz Med Wochenschr. 1996 Jul 9;126(27-28):1210-5.
Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria.
Monath TP, Nasidi A.
Am J Trop Med Hyg. 1993 Feb;48(2):274-99.
The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania.
Hutton G, Tediosi F.
Am J Trop Med Hyg. 2006 Aug;75(2 Suppl):119-30.
Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa.
Maire N, Tediosi F, Ross A, Smith T.
Am J Trop Med Hyg. 2006 Aug;75(2 Suppl):111-8.
Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness.
Prosser LA, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Messonnier ML, Lieu TA.
Pharmacoeconomics. 2008;26(2):163-78.
Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
Mlambo G, Maciel J, Kumar N.
Infect Immun. 2008 May;76(5):2018-24. Epub 2008 Mar 3.
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A.
Malar J. 2007 Aug 8;6:107.
Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis.
Naficy A, Rao MR, Paquet C, Antona D, Sorkin A, Clemens JD.
JAMA. 1998 Feb 18;279(7):521-5.
Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P.
Malar J. 2009 Jul 17;8:163.
International funding for malaria control in relation to populations at risk of stable Plasmodium falciparum transmission.
Snow RW, Guerra CA, Mutheu JJ, Hay SI.
PLoS Med. 2008 Jul 22;5(7):e142.
Measures of clinical malaria in field trials of interventions against Plasmodium falciparum.
Smith TA.
Malar J. 2007 May 2;6:53.
Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
Murray J, McFarland DA, Waldman RJ.
Bull World Health Organ. 1998;76(4):343-52.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on